Gambacorti-Passerini C - Search Results

1

Chronic myeloid leukemia: Second-line drugs of choice.

Gambacorti-Passerini C, Aroldi A, Cordani N, Piazza R. Gambacorti-Passerini C, et al. Am J Hematol. 2016 Jan;91(1):67-75. doi: 10.1002/ajh.24247. Am J Hematol. 2016. PMID: 26588811 Free article. Review.

2

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L. Gambacorti-Passerini CB, et al. Lancet Oncol. 2003 Feb;4(2):75-85. doi: 10.1016/s1470-2045(03)00979-3. Lancet Oncol. 2003. PMID: 12573349 Review.

3

Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels.

Gambacorti-Passerini C, Piazza R, D'Incalci M. Gambacorti-Passerini C, et al. Blood. 2003 Sep 1;102(5):1933-4; author reply 1934-5. doi: 10.1182/blood-2003-05-1629. Blood. 2003. PMID: 12930735 Free article. No abstract available.

4

Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib.

Piazza RG, Magistroni V, Gasser M, Andreoni F, Galietta A, Scapozza L, Gambacorti-Passerini C. Piazza RG, et al. Leukemia. 2005 Jan;19(1):132-4. doi: 10.1038/sj.leu.2403453. Leukemia. 2005. PMID: 15510211 No abstract available.

5

Development of c-Kit-expressing small-cell lung cancer in a chronic myeloid leukemia patient during imatinib treatment.

Gambacorti-Passerini C, Piazza R, Tornaghi L, Pilotti S, Pogliani E. Gambacorti-Passerini C, et al. J Natl Cancer Inst. 2004 Nov 17;96(22):1723-4. doi: 10.1093/jnci/djh330. J Natl Cancer Inst. 2004. PMID: 15547187 No abstract available.

6

Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate.

Perseghin P, Gambacorti-Passerini C, Tornaghi L, Dassi M, Pioltelli P, Parma M, Colnaghi F, Giudici G, Elli E, Fumagalli M, Ponchio L, Biondi A, Pogliani EM. Perseghin P, et al. Transfusion. 2005 Jul;45(7):1214-20. doi: 10.1111/j.1537-2995.2005.00175.x. Transfusion. 2005. PMID: 15987369

7

Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients.

Piazza RG, Magistroni V, Andreoni F, Franceschino A, Tornaghi L, Varella-Garcia M, Bungaro S, Colnaghi F, Corneo G, Pogliani EM, Gambacorti-Passerini C. Piazza RG, et al. Leukemia. 2005 Nov;19(11):1985-7. doi: 10.1038/sj.leu.2403928. Leukemia. 2005. PMID: 16121215 No abstract available.

8

Prognostic variables in patients with chronic myeloid leukemia treated with imatinib.

Gambacorti-Passerini C. Gambacorti-Passerini C. Haematologica. 2006 Feb;91(2):145a. Haematologica. 2006. PMID: 16461289 No abstract available.

9

Imatinib failed to eradicate chronic myeloid leukemia in a patient with minimal residual disease.

Franceschino A, Tornaghi L, Piazza R, Pogliani E, Gambacorti Passerini C. Franceschino A, et al. Haematologica. 2006 Jun;91(6 Suppl):ECR14. Haematologica. 2006. PMID: 16785120 No abstract available.

10

The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years.

Piazza RG, Magistroni V, Franceschino A, Andreoni F, Tornaghi L, Colnaghi F, Corneo G, Pogliani EM, Gambacorti-Passerini C. Piazza RG, et al. Blood Cells Mol Dis. 2006 Sep-Oct;37(2):111-5. doi: 10.1016/j.bcmd.2006.06.002. Epub 2006 Aug 14. Blood Cells Mol Dis. 2006. PMID: 16908206 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

359 results

Search Page